Michael Rice - BioLife Solutions CEO and President and Director
| BLFS Stock | USD 27.16 0.10 0.37% |
CEO
Mr. Michael Rice is the President, Chief Executive Officer, Director of the Company. Mr. Rice has more than 30 years of leadership and entrepreneurial experience in the medical and high tech industries. He was most recently the senior business development manager for medical and wireless products at AMI Semiconductor, from October 2004 to August 2006. From October 2000 to August 2006, Mr. Rice also served as the director of marketing and business development at Cardiac Science, Inc., a manufacturer of automated external defibrillators. Prior to that, from May 1998 to October 2000, he was the Vice President, Sales and Marketing for TEGRIS Corporationrationration, a privately held network services provider. Mr. Rice also spent 12 years, from May 1986 to May 1998 at Physio Control Corporation in several sales and marketing management roles prior to its acquisition by Medtronic Inc. The Board has determined that Mr. Rice should serve as a director because it values managements insight.. since 2017.
| Age | 61 |
| Tenure | 7 years |
| Address | 3303 Monte Villa Parkway, Bothell, WA, United States, 98021 |
| Phone | 425 402 1400 |
| Web | https://www.biolifesolutions.com |
BioLife Solutions Management Efficiency
The company has return on total asset (ROA) of (0.0597) % which means that it has lost $0.0597 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1504) %, meaning that it created substantial loss on money invested by shareholders. BioLife Solutions' management efficiency ratios could be used to measure how well BioLife Solutions manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.42 in 2024. Return On Capital Employed is likely to drop to -0.2 in 2024. At this time, BioLife Solutions' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 306.7 M in 2024, whereas Intangible Assets are likely to drop slightly above 19.5 M in 2024.Similar Executives
| Found 12 records | CEO Age | ||
| Michael Farrell | ResMed Inc | 48 | |
| Eric Green | West Pharmaceutical Services | 54 | |
| Christopher Simon | Haemonetics | 60 | |
| Albert White | The Cooper Companies, | 51 | |
| James Clemmer | AngioDynamics | 60 | |
| Robert Weiss | The Cooper Companies, | 74 | |
| David Endicott | Alcon AG | 59 | |
| Brian McKelligon | Akoya Biosciences | 55 | |
| Michael Carrel | AtriCure | 53 | |
| Stephan Tanda | AptarGroup | 59 | |
| Linda Tharby | Repro Med Systems | 56 | |
| Albert III | The Cooper Companies, | 54 | |
Management Performance
| Return On Equity | -0.15 | ||||
| Return On Asset | -0.0597 |
BioLife Solutions Leadership Team
Elected by the shareholders, the BioLife Solutions' board of directors comprises two types of representatives: BioLife Solutions inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioLife. The board's role is to monitor BioLife Solutions' management team and ensure that shareholders' interests are well served. BioLife Solutions' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioLife Solutions' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Aby Mathew, Chairman of Scientific Advisory Board, CTO and Sr. VP | ||
| Sarah JD, Chief Officer | ||
| Troy Wichterman, Chief Officer | ||
| Geraint Phillips, Senior Operations | ||
| Todd Berard, Vice President of Marketing | ||
| Karen Foster, Vice President - Operations | ||
| Troy CPA, Chief Officer | ||
| Sean Werner, Chief Officer | ||
| Marcus Schulz, Chief Officer | ||
| Michael Rice, CEO and President and Director | ||
| Roderick Greef, Interim CFO, Interim Secretary |
BioLife Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BioLife Solutions a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.15 | ||||
| Return On Asset | -0.0597 | ||||
| Profit Margin | (0.31) % | ||||
| Operating Margin | (0.05) % | ||||
| Current Valuation | 1.26 B | ||||
| Shares Outstanding | 46.39 M | ||||
| Shares Owned By Insiders | 1.93 % | ||||
| Shares Owned By Institutions | 99.56 % | ||||
| Number Of Shares Shorted | 2.68 M | ||||
| Price To Earning | 173.59 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for BioLife Stock Analysis
When running BioLife Solutions' price analysis, check to measure BioLife Solutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLife Solutions is operating at the current time. Most of BioLife Solutions' value examination focuses on studying past and present price action to predict the probability of BioLife Solutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLife Solutions' price. Additionally, you may evaluate how the addition of BioLife Solutions to your portfolios can decrease your overall portfolio volatility.